Galyan Bio
http://www.galyan.bio Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to id...
Galyan Bio Plans to Start Clinical Testing of Oral Therapy in 2022
Galyan Bio plans to initiate a clinical trial of a small molecules candidate that aims to slow the progression of Huntington’s disease next year, working in with Bicoll GmbH.
Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to identify new scaffold for first-in-class clinical candidates. The new treatments interfere in the protein quality control system and are subsequently also useful for healthy aging.
media@galyan.bio
Contacts /
For more information, please contact:
Rohit Shyam
Chief Business Officer